Who We Are

Our Purpose

At Eicos Sciences, we are focused on the development and commercialization of life-changing prostacyclin therapies to improve patient outcomes in medical conditions where there are limited or no treatment options.


SHAL JACOBOVITZ, Chief Executive Officer

  • 30+ years experience in the pharma industry in leadership roles (Actelion, F. Hoffman LaRoche, Abbott Canada, Nordic Labs & Marion Merrill Dow [now Aventis])
  • Former CEO of the American College of Cardiology (2013 – 2018) and led the 52,000+ member organization in its mission to transform cardiovascular care
  • Former President of Actelion Pharmaceuticals (2004 – 2013), acquired by J&J for $30B

WADE BENTON, PHARM.D., Chief Development Officer 

  • 20 years experience in drug development and academic research in Systemic Sclerosis, PAH, Cystic Fibrosis, Pediatrics
  • 15 years experience developing and commercializing prostacyclin analogs

KEVIN CHRISTAL, Chief Operating Officer

  • 20 years experience in commercial operations and business development spanning numerous disease areas
  • 15 years experience developing and commercializing prostacyclin analogs

ESTELA ALVAREZ, PH.D., Vice President, Quality and Analytical Development

  • 25+ years of experience in quality (QA and QC) and analytical development in the biotechnology and pharmaceutical industry
  • Successfully launched three pharmaceutical products from Phase II/ III to the market in three companies

PATRICK HALL, Vice President, Market Access

  • Over 25 years of market access and commercialization experience in the pharmaceutical and medical device markets focused on specialty orphan drug launches and commercialization in start-up biopharmaceutical manufacturers
  • Built and led the market access teams for multiple successful product launches at Actelion Pharmaceuticals, Global Blood Therapeutics, ChemoCentryx Biopharmaceuticals, and Clene Nanomedicine, Inc.

CHRISTA-LYNN VAMPOLA, PH.D., Vice President, Regulatory and Clinical Science

  • 20 years experience in pharmaceutical medical and clinical sciences and academic research
  • 10 years experience developing and commercializing prostacyclin analogs

ALLISON WIDLITZ, PA-C, M.S., Vice President, Medical Affairs

  • 15+ years in the pharmaceutical industry preparing for new product launches, building and leading global field-based medical teams supporting drug development and commercialization
  • Board certified physician assistant for 30 years with strong scientific background and clinical experience across a broad range of therapeutic areas